Cypher’s Impact On Regulatory, Reimbursement Landscape
This article was originally published in The Gray Sheet
Executive Summary
During its rise and fall as the first device on the “blockbuster” drug-eluting stent market, Cordis' Cypher sirolimus-eluting coronary stent helped break new ground on both regulatory and reimbursement fronts.
You may also be interested in...
Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS
The device is one the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.
Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS
The device is one of the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.
FDA And CMS Parallel Reviews Will Begin With Device Pilot Program
FDA and CMS' consideration of parallel medical product reviews will begin in earnest with a planned pilot program for devices, the agencies say